Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

Gilead Sciences will invest $275m for a 49.9% stake in the UofT and UCSF-linked company as part of a $1.47bn deal to potentially purchase Pionyr outright.

Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.

The carmaker has followed up a $100m investment two years ago with a pledge to provide up to $200m for the Stanford-originated solid-state battery developer.

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Existing backer GV returned to take part in a $100m round for the Stanford spinout that also attracted new investor Regeneron Pharmaceuticals.

TU Munich's air taxi developer has added $35m from Bailie Gifford to a $240m first tranche led by Tencent in March, and is now valued above $1bn.

University of Minnesota has invested in UBC spinout AbCellera's series B round that also included Eli Lilly.

Haier Financial Holdings has backed a $254m funding round for CloudWalk, a spinout of Chinese Academy of Sciences.